TABLE 3.
Comparison of clinical characteristics and outcomes of patients with MSSA-B receiving vancomycin treatment versus beta-lactam antibiotic treatment in the matched case-control study
| Characteristic | Objective matching scoring system
|
Propensity score system
|
||||
|---|---|---|---|---|---|---|
| Vancomycin treatment (n = 27)a | Beta-lactam treatment (n = 54)a | P value | Vancomycin treatment (n = 27)a | Beta-lactam treatment (n = 54)a | P value | |
| Propensity score for vancomycin treatment (mean ± SD) | 0.17 ± 0.10 | 0.13 ± 0.14 | 0.16 | 0.17 ± 0.10 | 0.18 ± 0.14 | 0.77 |
| Age (yr, mean ± SD) | 52.1 ± 18.4 | 52.9 ± 17.6 | 0.85 | 52.1 ± 18.4 | 51.6 ± 17.6 | 0.92 |
| Male gender | 16 (59) | 36 (67) | 0.51 | 16 (59) | 40 (74) | 0.17 |
| Community-acquired infection | 12 (44) | 27 (50) | 0.64 | 12 (44) | 21 (39) | 0.63 |
| Length of hospital stay before SAB | ||||||
| <72 h | 12 (44) | 27 (50) | 0.64 | 12 (44) | 21 (39) | 0.63 |
| 3-7 days | 3 (11) | 4 (7) | 0.68 | 3 (11) | 4 (7) | 0.68 |
| 8-28 days | 9 (30) | 17 (35) | 0.87 | 9 (30) | 23 (43) | 0.42 |
| >28 days | 4 (15) | 6 (11) | 0.72 | 4 (15) | 6 (11) | 0.72 |
| McCabe classification | ||||||
| Nonfatal | 6 (22) | 13 (24) | 0.85 | 6 (22) | 16 (30) | 0.48 |
| Ultimately fatal | 13 (48) | 30 (56) | 0.53 | 13 (48) | 31 (57) | 0.43 |
| Rapidly fatal | 8 (30) | 11 (20) | 0.35 | 8 (30) | 7 (13) | 0.13 |
| Main underlying diseases | ||||||
| Solid tumor | 5 (19) | 11 (20) | 0.84 | 5 (19) | 4 (7) | >0.99 |
| Hematologic malignancy | 7 (26) | 15 (28) | 0.86 | 7 (26) | 21 (39) | 0.25 |
| Liver cirrhosis | 5 (19) | 10 (19) | >0.99 | 5 (19) | 6 (11) | 0.85 |
| End stage renal disease | 3 (11) | 7 (13) | 0.81 | 3 (11) | 7 (13) | 0.81 |
| Cardiovascular disease | 7 (26) | 8 (15) | 0.23 | 7 (26) | 10 (19) | 0.44 |
| Primary sites of infection | ||||||
| Unknown | 10 (37) | 22 (41) | 0.75 | 10 (37) | 15 (28) | 0.40 |
| Catheter-related infection | 3 (11)b | 8 (15)b | 0.74 | 3 (11)c | 16 (30)c | 0.06 |
| Pneumonia | 3 (11) | 7 (13) | 0.81 | 3 (11) | 4 (7) | 0.68 |
| Soft tissue infection | 2 (7) | 5 (9) | 0.78 | 2 (7) | 10 (19) | 0.32 |
| Surgical wound infection | 2 (7) | 4 (7) | >0.99 | 2 (7) | 5 (9) | 0.78 |
| Eradicated foci of infection | 8 (30) | 13 (24) | 0.59 | 8 (30) | 22 (41) | 0.33 |
| Neutropenia | 8 (30) | 15 (28) | 0.78 | 8 (30) | 16 (30) | 0.92 |
| Infection acquired in intensive care unit | 5 (19) | 7 (13) | 0.52 | 5 (19) | 5 (9) | 0.29 |
| Previous admission history | 10 (37) | 21 (39) | 0.87 | 10 (37) | 30 (56) | 0.12 |
| Previous antibiotic use | 15 (56) | 22 (41) | 0.21 | 15 (56) | 40 (74) | 0.09 |
| Previous surgery | 3 (11) | 7 (13) | 0.81 | 3 (11) | 8 (15) | 0.65 |
| Defervescence (days, mean ± SD) | 5.0 ± 6.2 | 4.0 ± 3.1 | 0.41 | 5.1 ± 6.3 | 3.4 ± 2.1 | 0.14 |
| Duration of treatment (days, mean ± SD) | 20.2 ± 12.4d | 23.0 ± 14.4d | 0.49 | 20.2 ± 12.4e | 20.8 ± 12.1e | 0.86 |
| Combination treatment | 0 (0) | 0 (0) | >0.99 | 0 (0) | 0 (0) | >0.99 |
| Metastatic infection | 8 (30) | 12 (22) | 0.47 | 8 (30) | 15 (28) | 0.86 |
| Infective endocarditis | 4 (15) | 3 (6) | 0.21 | 4 (15) | 1 (2) | 0.04 |
| Overall deaths | 11 (41) | 8 (15) | 0.009 | 11 (41) | 10 (19) | 0.03 |
| 30-day deaths | 9 (33) | 7 (13) | 0.03 | 9 (33) | 6 (11) | 0.02 |
| 14-day deaths | 9 (33) | 7 (13) | 0.03 | 9 (33) | 4 (7) | 0.008 |
| SAB-related deaths | 10 (37) | 6 (11) | 0.006 | 10 (37) | 6 (11) | 0.006 |
| Deaths not related to SAB | 1 (4) | 2 (4) | >0.99 | 1 (4) | 5 (9) | 0.66 |
| Recurrence | 0 (0) | 3 (6) | 0.55 | 0 (0) | 2 (4) | 0.56 |
| Cure | 16 (59) | 44 (82) | 0.03 | 16 (59) | 43 (80) | 0.05 |
a
Data are presented as the number (%) of patients unless indicated otherwise.
b
Catheter was removed in 10 (91%) of 11 patients with catheter-related infection.
c
Catheter was removed in 16 (84%) of 19 patients with catheter-related infection.
d
A total of 62 patients, excluding 19 patients who died, were included in this analysis.
e
A total of 60 patients, excluding 21 patients who died, were included in this analysis.